Evidence map›Paper›PMID 39262145›Full record

ArticleActa dermato-venereologica2024

Brian S Kim, Sonja Ständer, Kenji Kabashima, Jennifer A Mohawk, Sherri So, Joana Goncalves, Nilam Shah, Catherine Munera, Joseph C Punzalan, Romelia Argudo and 1 more

Abstract read
In one paragraph

Article in Acta dermato-venereologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Neural therapy in notalgia paresthetica.Archives of dermatological research · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Brian S KimIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Sonja StänderUniversity Hospital Münster, Münster, Germany.
Kenji KabashimaKyoto University Graduate School of Medicine, Kyoto, Japan.
Jennifer A MohawkCara Therapeutics, Stamford, CT, USA.
Sherri SoCara Therapeutics, Stamford, CT, USA.
Joana GoncalvesCara Therapeutics, Stamford, CT, USA. jgoncalves73@gmail.com.
Nilam ShahCara Therapeutics, Stamford, CT, USA.
Catherine MuneraCara Therapeutics, Stamford, CT, USA.
Joseph C PunzalanAplusA Bell Falla, Newark, NJ, USA.
Romelia ArgudoAplusA Bell Falla, Newark, NJ, USA.
Mark LebwohlIcahn School of Medicine at Mount Sinai, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Notalgia paresthetica (NP) is a sensory neuropathy characterized by chronic pruritus, skin pain, and other pathologic sensations affecting the mid-to-upper back. NP may be under-recognized and under-diagnosed, with limited data available on its symptom presentation and treatment patterns. NP-DERM was an internet-based survey of dermatologists (n = 650) from 8 different countries on their perspectives on NP symptoms and current treatment practices. Dermatologists typically treated a median of 12 patients with NP per month. Dermatologists reported that itch (pruritus) was the most common symptom for their patients with NP, followed by hyperpigmentation and sensitive skin. The most burdensome NP symptom was pruritus, followed by burning or hot sensation, and painful or raw skin. The most prescribed treatments included non-medicated skin care, topical corticosteroids, oral antihistamines, medicated topicals, and gabapentin or pregabalin. Physicians reported low satisfaction with available treatments. The most common reason for physicians to discontinue patients' therapy was lack of response.

Indexed as

DermatologistsHealth Care SurveysPractice Patterns, Physicians'PruritusFemaleHumansMaleMiddle AgedParesthesiaSymptom BurdenTreatment Outcome

Identifiers

PMID39262145
PMCPMC11411784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.